Accès ouvert
2026
article
OpenAlex
Jinguan Lin, Song Qu, Kunyu Yang, Tao Zhang et autres
BACKGROUND: Effective treatment options remain limited for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), including patients who have progressed after platinum-based chemotherapy and systemic-therapy-naïve patients. This Phase Ib trial evaluates the efficacy and safety of finotonlimab, …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Cuige Gao, Jiang Yi, Adam Abdul Hakeem Baidoo, Dongfang Liu et autres
Objectives: The rapid emergence of SARS-CoV-2 prompted accelerated vaccine development, with neutralization assays serving as essential tools to evaluate vaccine-induced immune responses. Methods: analysis of a Phase I/II trial evaluated the immunogenicity of a bivalent SARS-CoV-2 protein vaccine. We assessed vaccine immunogenicity …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Lixin Yan, Jiang Yi, Dongfang Liu, Jian Li et autres
Background: Following SARS-CoV-2 infection, the necessity of vaccination after natural infection remains uncertain. However, many asymptomatic individuals who test negative virologically may nevertheless receive vaccination without being aware of their prior infection. Investigating the implications for vaccine safety and efficacy is crucial. …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Chuanhua Zhao, Yanqiao Zhang, Gang Wang, Jinfang Zheng et autres
We aimed to assess the tolerability and efficacy of finotonlimab (an anti-programmed cell death protein-1 antibody) in combination with SCT510, a bevacizumab biosimilar, versus sorafenib in unresectable advanced HCC. This randomized phase 2 and 3 study (ClinicalTrials.gov, NCT04560894; Chinadrugtrials.org.cn, CTR20201976 and CTR20201974) …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Rui Wang, Yuan Lyu, Meng Chen, Lili Sun et autres
There are challenges in selecting SARS-CoV-2 vaccine compositions, primarily due to divergent infection or vaccination history and immunological biases toward previous strains. In this study, we evaluated humoral immune responses induced by variant-based monovalent vaccines as booster shots in mice previously vaccinated …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Sen He, Die Wu, Chengshuai Niu, Xinchao Liu et autres
BACKGROUND: Recombinant erythropoietin (rEPO) is commonly used in therapy but may be abused in sports to enhance endurance. In doping analysis, rEPO can be detected in human urine or blood samples at picogram (pg) levels based on its slightly higher molecular weight …
cn, fr
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jorge Díaz, Allex Jardim da Fonseca, Lixin Yan, Dongfang Liu et autres
Background/Objective: This study was a randomized, double-blinded, placebo-controlled Phase II trial conducted to evaluate the efficacy of neutralizing monoclonal antibody (SCTA01) in high-risk outpatients diagnosed with COVID-19. Methods: The primary endpoint was the proportion of patients who experienced COVID-19-related hospitalization (defined as …
us, br, cn
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Cuige Gao, Jiang Yi, Adam Abdul Hakeem Baidoo, Dongfang Liu et autres
SARS-CoV-2 led to the swift development of vaccines, and neutralization assays played a crucial role in assessing their effectiveness. A post-hoc analysis of a Phase I/II trial evaluated the immunogenicity of a bivalent SARS-CoV-2 protein vaccine. We assessed vaccine immunogenicity using live …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Baohui Han, Lin Wu, Runxiang Yang, Hongbo Wu et autres
Background: Lung cancer is the most common cancer in the world, and non-small cell lung cancer (NSCLC) constitutes about 80-85%. In this phase III trial, we evaluate the efficacy and safety of anti-programmed cell death-1 (PD-1) monoclonal antibody (SCT-I10A) plus docetaxel compared …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Felipe Dal‐Pizzol, Suzana Margareth Lobo, Christopher Lucasti, Adam Abdul Hakeem Baidoo et autres
Background: Hospitalized patients with severe COVID-19 are at high risk of clinical deterioration. Methods: A global, randomized, double-blinded, and placebo-controlled phase II trial that investigated the clinical efficacy of SCTA01, an Fc-modified monoclonal antibody, in patients hospitalized with severe COVID-19 during the …
br, cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Yunqi Yao, Xiaoning Yang, Jing Li, Erhong Guo et autres
Background/Objectives: Finotonlimab (SCTI10A) is a humanized anti-PD-1 antibody tested in Phase III trials for several solid tumor types. Methods: This study characterized the in vitro and in vivo efficacy, Fc-mediated effector function, and non-clinical PK/PD properties of finotonlimab. Results: The results demonstrated …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Xiaoli Zhang, Jilei Jia, Gaojian Chen, Dan Meng et autres
SCTV01E, a novel SARS-CoV-2 tetravalent protein vaccine containing recombinant spike proteins of Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron BA.1 (B.1.1.529.1) variants and SCTVA02B adjuvant, has received Emergency Use Authorization (EUA) in China and the United Arab Emirates (UAE) as a …
cn
(code pays fourni par la source)